key: cord-0867587-yja5tl0m authors: Pérez-Campos Mayoral, Laura; Hernández-Huerta, María Teresa; Papy-García, Dulce; Barritault, Denis; Zenteno, Edgar; Sánchez Navarro, Luis Manuel; Pérez-Campos Mayoral, Eduardo; Matias Cervantes, Carlos Alberto; Martínez Cruz, Margarito; Mayoral Andrade, Gabriel; López Cervantes, Malaquías; Vázquez Martínez, Gabriela; López Sánchez, Claudia; Pina Canseco, Socorro; Martínez Cruz, Ruth; Pérez-Campos, Eduardo title: Immunothrombotic dysregulation in chagas disease and COVID-19: a comparative study of anticoagulation date: 2021-06-10 journal: Mol Cell Biochem DOI: 10.1007/s11010-021-04204-3 sha: 681045a7f06ec3c7f36a116f6cc72752e86d0505 doc_id: 867587 cord_uid: yja5tl0m Chagas and COVID-19 are diseases caused by Trypanosoma cruzi and SARS-CoV-2, respectively. These diseases present very different etiological agents despite showing similarities such as susceptibility/risk factors, pathogen-associated molecular patterns (PAMPs), recognition of glycosaminoglycans, inflammation, vascular leakage hypercoagulability, microthrombosis, and endotheliopathy; all of which suggest, in part, treatments with similar principles. Here, both diseases are compared, focusing mainly on the characteristics related to dysregulated immunothrombosis. Given the in-depth investigation of molecules and mechanisms related to microthrombosis in COVID-19, it is necessary to reconsider a prompt treatment of Chagas disease with oral anticoagulants. Chagas disease (CD) and COVID-19 caused by Trypanosoma cruzi and SARS-CoV-2, respectively, have the common characteristic of dysregulated immunothrombosis. Here, we have integrated the reported evidence of both, which leads us to consider that the possibility of anticoagulant treatment in Chagas disease can prevent the immunothrombosis stage. Although the prevalence of immunothrombotic dysregulation in Chagas disease and COVID- 19 is not yet known, the proportion depends on the method of detection and the group studied. As an example, the chronic cardiac form of CD was inferred through echocardiography in a study of ischemic cerebrovascular events (ICE); the authors found cardioembolism as a factor associated with 20% of CD cases [1] , however, could reach 44% [2] . Even though the reported evidence is extremely diverse, it currently indicates that the incidence of deep vein thrombosis (DVT) in COVID-19 patients ranges between 6 and 66% [3] . In mild/moderate COVID-19, deep venous thrombosis (DVT) was found in the lower extremities by duplex ultrasound, with a rate of around 25% [4] , but it could reach as much as 82% by computed tomography venography (CTV) and doppler ultrasound [5] . In pulmonary vessels, it is 46% [6] , while in arterial thromboses, it is 9.6% [7] . Immunothrombosis has been reported in COVID-19 [8] and Chagas disease [9, 10] . Immune-driven thrombosis, immunothrombosis, or thrombo-inflammation [11] has the characteristics of upregulation of monocytes/macrophages and vessel wall-exposing podoplanin, activating C-type lectin-like receptor-2 (CLEC-2) in platelets on the microvasculature [12] , which causes endotheliopathy and microthrombi [13] . The expression of podoplanin, known as gp38, T1α, D2-40, or Aggrus, is also upregulated during inflammation by cytokines and other compounds in different cells, such as T helper cells, fibroblasts, epithelial cells, and in fibroblastic reticular cells in secondary lymphoid organs [14] . In viral diseases such as dengue and H5N1 influenza, CLEC-2 binds fucoidans in a similar way to a ligand [15, 16] . These glycans interact with viruses, such as the dengue virus, which binds to CLEC-2 on platelets [16] . In the dengue virus, interaction with CLEC-2 on platelets releases exosomes and microvesicles that trigger the activation of CLEC5A and TLR2, and promote the release of neutrophil-derived extracellular traps (NETs) in addition to the release of proinflammatory cytokines in neutrophils and macrophages [12] . NETs, due to the content of DNAhistone complexes and high mobility group box 1 proteins (HMGB1), are cytotoxic and procoagulant [17, 18] . In SARS-CoV-2 infection, the spike protein induces platelet activation [19] . This is explained by the fact that platelets have ACE2-TMPRSS2 receptor-protease axis [20] , and also, platelets favour increases in fibrinogen, von Willebrand factor, and factor XII [21] , this favours the prothrombotic state [22] . In COVID-19, activation of the complement through mannose-binding lectin (MBL) has been reported [23] . In SARS-CoV, MBL initiates the complement activation in a calcium-dependent and a mannan-inhibitable manner [24] . MBL circulates in a complex with mannose-associated serine protease (MASP)-1 and MASP-2. MASP-1 can activate coagulation through factor XIII (FXIII) and thrombin-activatable fibrinolysis inhibitor (TAFI) [25] . That is, MBL acts from a different route to that of heparin (thrombin and factor Xa), which could explain thromboembolic events in patients with thromboprophylaxis. In the severe form of Chagas disease, a greater binding capacity of MBL was observed, which could facilitate the internalization of T. cruzi in cardiomyocytes [26] Furthermore, MASP-2 deficiency does not represent an important mechanism against T. cruzi infection [27] . A disparity is assumed since the etiological agent is different, added to the large inter-individual and inter-population differences between Chagas disease and COVID-19. Nevertheless, when these illnesses are compared regarding susceptibility/risk, ethnicity, age, sex, and other co-morbidities, there are similarities in both diseases. For example, there are genetic polymorphisms associated with the protection or greater risk of damage, as in Chagas disease in which the genetic variant of CCL5 and CCR1 + confers protection, while CCR5 deficiency is associated with cardiac damage [28] . On the other hand, depending on the population studied, a higher or lower risk may be related to variants CCL2, MBL, CCL5, AHSG, and IL4 in COVID-19 [29] . We compare and show a series of different factors in both infections (Table 1) . Chagas disease (CD) is a neglected tropical disease, with an estimated 6 to 7 million people infected with T. cruzi worldwide [30] . In 2006, the number of cases recorded in Latin America was 7,544,500 [31] . Migration, blood transfusion, and organ transplantation have caused the spread of CD not only in Latin America but also in many other places around the world, e.g. the prevalence per in some European countries is 2.7-4.8 in Spain; 2.0-4.8 in Switzerland; 1.3-1.7 in France; and 1.3-2.4 in The United Kingdom [32] . In a post-mortem study in Sao Paulo Brazil with 1,345 studied cases of Chagas heart disease, a thromboembolic phenomenon was found in 44% of patients, and this included infarction at different phases of evolution and cardiac thrombosis in 27% of cases [2] . The protocol for treatment recommends just benznidazole and nifurtimox [33] ; however, anticoagulants or antiplatelet agents should be considered in addition. In Chagas disease, hypercoagulability is characterized by an increase in the prothrombin fragment 1 + 2 (F1 + 2), endogenous thrombin potential (ETP), D-dimer, and plasmin-antiplasmin complexes (PAP), before or after treatment [13, 34] . Thrombin activation causes a procoagulant and fibrinolysis pathway. Furthermore, platelet hyperactivity and endothelial damage occur, which are correlated with increases in circulating microparticles from endothelial cells, macrophages, and CD8 + T cells [35] , PAC-1 (GPIIb/IIIa), and CD62P (P-selectin) [36] . In the initial host-trypanosome interaction, the infective trypomastigote recognizes 2,3-sialyl residues [37] and releases neuraminidase, which can desialylate myocardial or human vascular endothelial cells, and mediate the development of Chagas heart disease [38] . Different mechanisms affect the invasion process of trypomastigote forms in cardiomyocytes by T. cruzi. One of the known mechanisms is through glycosaminoglycan-binding or heparin-binding proteins in the amastigote and trypomastigote forms of T. cruzi, which bind to cardiomyocyte heparan sulphate proteoglycans (HSPG) [39, 40] . Table 1 Comparative factors between Chagas disease and COVID-19 Chagas disease (CD) Age and Gender This varies in parallel with the pathology and the studied group, e.g. in a study of Chagasic megaesophagus in Brazil, men had a higher frequency (54%) and those under 31 years of age had a prevalence of 4.2% [88] . In a population from Venezuela, a 4.2% with heart disease in a four-year follow-up was found [89] Higher mortality has been observed in men than in women in the US and 10 European regions [90, 91] In addition, no statistical differences had been found in viral load according to gender and age [92] . Still, other studies differ slightly in viral load; women present higher viral load than men [93] Comorbidities Among the most frequent concurrent diseases in CD in the elderly are hypertension, osteoporosis, osteoarthritis, and dyslipidaemia [94] The proportion of comorbidities depends on the population studied. Among the most frequent conditions experienced are hypertension, diabetes, chronic kidney disease, chronic liver disease, chronic obstructive pulmonary disease, cardiovascular disease, and cerebrovascular disease [95] Prevalence of asymptomatic infection The prevalence of CD in asymptomatic blood donors is 4.3% in Mexico [96] In asymptomatic patients with chronic CD in Brazil, the prevalence of cardiovascular disorders ranges from 2 to 77% [97] Incidence rates of asymptomatic infection range from 1.6 to 56.5% in China and the USA, respectively [98] Susceptibility/risk HLA Genetic susceptibility to CD depends on ethnic group, e.g. DRB1 * 08 and DRB1 * 01, DQB1 * 05:01 in Venezuela. HLA-B39 b, HLA-B35 b, HLA-DR4, and HLA-DR16 in Mexico. A31, B39, and DR8 in Latin-American mestizos [99] HLA-A*25:01, HLA-B*46:01, and HLA-C*01:02 have a lower number of binding peptides in antigen presentation, which could be associated with greater severity of the disease [100] Genetic polymorphisms In Brazil, the microsatellite locus D6S291 of the major histocompatibility complex (MHC) and in the microsatellite of the IL-10, allelic differences were found in CD [101] The genetic variant of L18 rs360719 causes the loss of the binding site of the octamer transcription factor (OCT)-1 [102] . In the Latin-American population, L18 rs360719 is related to susceptibility by T. cruzi infection [103] The gene variant of IL17A rs2275913 binds to the nuclear factor-activated T cells (NFAT) [104] . In the Latin-American population, IL17A rs2275913 is related to T. cruzi susceptibility. [105] . In Brazil, the variants IL17A and IL17F are associated with the development of cardiomyopathy [106] In the African/African-American population, p.Arg514-Gly, a polymorphism of ACE2, is associated with cardiovascular and pulmonary conditions [107] In Genome-wide Association Study (GWAS) in Italian and Spanish hospitals, a 3p21.31 gene cluster encompassed the SLC6A20, LZTFL1, CCR9, FYCO1, CXCR6, and XCR1 genes [108] Genetic polymorphisms of Interferon-γ Production In the Brazilian population, genotypes and alleles of IL12B and IL-10 could be associated with a failure to regulate Th1 responses, IFNγ production, and an increased risk of chronic CD cardiomyopathy [109] Interferon-gamma gene (IFNG) + 874 T/A polymorphism could be related to a predisposition to CD in the South American population [110] The single nucleotide polymorphism (SNP) rs6598045 of the interferoninduced transmembrane protein 3 (IFITM3) gene correlates with COVID-19 fatality rates [111] Populations with a low allele frequency of rs1990760 (T allele) in IFIH1 (InterFeron-Induced Helicase 1; MDA5) are associated with less IFN-beta expression and potential susceptibility to COVID-19 infection [112] ABO blood group system Inconclusive studies found an increase in blood group B patients dying suddenly from CD [113] The histo-blood group system explored by GTA, GTB, FUT II, and FUT III glycosyltransferases found that B plus AB secretor phenotypes are related to megaesophagus and megacolon in CD [114] GWAS found blood group A is associated with COVID-19 and respiratory failure [111] Type A blood is associated with the risk of in-hospital death [115] Table 1 (continued) Chagas disease (CD) Ethnicity CD with megacolon, calibre and length of the rectosigmoid depends on altitude, ethnicity, and diet [116] COVID-19 presents an increased risk depending on the population studied, e.g. Black and Asian compared to white subjects had increased risk infection of COVID-19 [117] In Mexico, native peoples have a higher risk of death due to COVID-19 [118] Dysregulated immunothrombosis Hypercoagulability The activation of haemostasis is related to the activation and increase of various molecules, e.g. Lys-bradykinin is released by cruzipain, and this could activate contact factors and, therefore, the intrinsic pathway of coagulation [119, 120] . In addition, there is prothrombotic activation with an increase of endogenous thrombin potential (ETP) and F1 + 2 levels, plasmin-antiplasmin complexes (PAP) [9, 34] , PAI-1, and fibrinogen [121] In structural studies, it has been reported that platelets are not only related to microthrombi but also erythrocytes and amyloid microclots. [122] A study of Post-acute COVID-19 syndrome in Bergamo, Italy, found hypercoagulation in 17% of patients with D-dimer values that increased more than two times above 500 ng/mL [123] . In addition, ischemic cardiovascular events are increasing in COVID-19 [124] , myocardial injury and elevated troponin levels are also reported [125] Inflammation and vascular leakage Trypomastigotes boost their infectivity through activation of the mast cell/ kallikrein-kinin system pathway, resulting in inflammatory oedema [126] At the site of infection by T cruzi, C5a, and bradykinin are released and modulate innate and adaptive immunity, inflammation, and plasma leakage [127] The severity of COVID-19 is related to increased inflammation markers such as C-reactive protein (CRP), interleukin-6, nuclear factor kappa B (NFκB), and tumour necrosis factor-alpha (TNFα) as well as multiorgan failure [128] Mid-Regional proAdrenomedullin (MR-proADM), a marker of endothelial integrity and vascular leakage, is also related to severity and mortality in COVID-19 [129] During COVID-19, inflammation, vasodilation, hypotension, and plasma leakage may be due to the bradykinin system, in particular des-Arg9-BK, which acts on Bradykinin 1 (B1) receptor [130] T. cruzi infection also causes generalized vasculitis with peculiar characteristics in the myocardium, such as vasospasm, myocardial ischaemia, myonecrosis, and platelet hyperaggregation. Therefore, activation of the extracellular signal-regulated kinase, activator-protein-1, endothelin-1, and cyclins release thromboxane (TX2) from T. cruzi [41, 42] . The COVID-19 pandemic caused by SARS-CoV-2 has resulted in more than 169 million confirmed infections and 3.5 million deaths worldwide as of May 29, 2021 [43] . SARS-CoV-2 entry depends on the ACE2 receptor and the serine protease TMPRSS2 for S protein priming [44] , as well as other proteins such as endosomal cysteine proteases cathepsins B/L (CTSB, CTSL) [45] . These molecules are primarily co-expressed in the respiratory tract, kidneys, heart, and gastrointestinal system [34] and show higher levels of ACE2 gene expression in the testes, thyroid, and adipose tissue [46] , as well as in arterial and venous endothelial cells, and arterial smooth muscle cells [47, 48] . The concept of dysregulation of immunothrombosis defines a vicious cycle of immune activation and formation of microthrombi [11] . Microthrombi have been reported in different tissues, in alveolar capillaries, kidneys, and glomerular capillaries; furthermore, they are accompanied by signs of disseminated intravascular coagulation despite anticoagulation [49] in pulmonary, hepatic, renal, and cardiac microvasculature [50] , in addition to pulmonary arterial thrombi [51] . Microthrombosis is assumed to be found in larger series in different extrapulmonary tissues, depending on the expression of ACE2 and TMPRSS2 [52] . In COVID-19 immunothrombosis, monocytes and neutrophils activate platelets and coagulation through ACE2 receptors and TMPRSS2 protease from the entry of the virus into the body [53] , particularly in pneumocytes and the endothelial cells. Microvascular dysfunction, apoptosis of endothelial cells, and mononuclear cells have been observed [54] , which may explain endothelial damage and the elevation of circulating endothelial cells in the presence of SARS-CoV-2 infection [55] . Regarding endothelial damage in non-critical patients in the non-intensive care unit (non-ICU), pro-angiogenic factors such as VEGF-A, PDGF-AA, and PDGF-AB/BB increase significantly, while critical patients in the ICU have significantly increased levels of biomarkers related to endotheliopathy such as angiopoietin-2, FLT-3L, and PAI-1 [56] . This is consistent with the pathological findings of severe endothelial injury associated with the intracellular SARS-CoV-2 virus and alveolar-capillary microthrombi [57] . COVID-19 is associated with hypercoagulability and thrombosis due to damaged endothelial cells through ACE2 receptors. Subsequently or simultaneously, when SARS-CoV-2 enters, its pathogen-associated molecular pattern (PAMP) can be recognized. This activates the innate and adaptive immune response, platelet activation, the release of neutrophil extracellular traps (NETs), the tissue factor release and contact pathway activation, the activation of the coagulation system and thrombin generation, complement activation, and the activation of the fibrinolytic and anticoagulant systems [58] . All these activation mechanisms are expressed to different degrees but integrate dysregulated immunothrombosis [59] and then thrombosis. In COVID-19 infection, hypercoagulability mimics disseminated intravascular coagulopathy and are characterized by thrombocytopenia and platelet hyperreactivity [19, 60] . Results are heterogeneous, depending on the severity of the patient, e.g. in initial presentations, abnormalities in prothrombin time, partial thromboplastin time, and platelet counts show little change [61] . Nevertheless, in patients with severe pneumonia and a poor prognosis, an elevated D-dimer and higher prothrombin time (PT) are observed [62] in up to 50% of patients [63] . A state of hypercoagulation and aberrant hyperfibrinolysis [64] is characterized by an increase in the activated partial thromboplastin time (APTT) and fibrinogen, with lower platelet count [65] and an increase in fibrin degradation products (FDP) [66] . The use of low molecular weight heparin (LMWH) is preferred over unfractionated heparin (UFH) for the treatment or reduction of an increased risk of venous thromboembolism (VTE) [67] ; however, direct oral anticoagulants (DOAC) (dabigatran, apixaban and rivaroxaban) and viral medications (lopinavir, ritonavir, or darunavir) are commonly used in COVID-19 patients, although DOAC plasma levels increase significantly, as observed in the Cremona study. Therefore, they suggest the use of parenteral anticoagulants [68] . In general, prophylactic anticoagulation (including oral, subcutaneous, or intravenous forms) in COVID-19 patients results in lower mortality [69] . Moreover, derivatives of heparin have been proposed. Heparinoids constituted of heparan, dermatan, and chondroitin sulphate, are found in plants and animals, and are also of synthetic origin [70] . In the production of low molecular weight heparin, two waste heparinoids are obtained: Danaparoid and Sulodexide. Danaparoid is 84% heparan sulphate [71] ; it inhibits activated factor X (Factor Xa) and activates factor II (Factor IIa) and has low cross-reactivity with antibodies associated with heparin-induced thrombocytopenia [72] . Sulodexide constituted of 80% heparan sulphate [73] , increases the effect of antithrombin III and heparin cofactor II [74] , and releases an inhibitor of the endothelial tissue factor pathway [75] . Another sub-group of heparinoids are Fucoidans, which have 30-60% sulphated polysaccharides [55] . These also increase the interaction of thrombin with Antithrombin III (AT-III) and heparin cofactor II (HC-II) [76] . Heparan sulphate is a heparinoid constituted of repeating units of disaccharide N-acetylglucosamine and glucuronic acid (1 → 4 linked) with alternatively sulphated domain structures [77] . Heparan sulphate and heparin are related to cell adhesion, recognition, migration, modulation of enzymatic activities, and anticoagulant activity [55] . A ubiquitous molecular component on the cell surface is heparan sulphate proteoglycans (HSPG) which are constituted of heparan sulphate (HS) polysaccharides attached to core protein by the global negative charge from HSPG. This facilitates interaction with viral molecules such as the herpes simplex virus, dengue virus, and coronaviruses [78] . SARS-CoV-2 recognizes 9-O-acetyl-sialic acid [79] and sulphated polysaccharides [80] . Various studies have reported the participation of heparin or heparan sulphate in initial virus adherence [81] , and heparin and enoxaparin also bind to the spike (S1) protein receptor-binding domain (S1 RBD) [82] . Low-molecular weight heparin is the best treatment for inhibiting microthrombosis in SARS-CoV-2 infections. In addition, heparin or its derivatives could be used to compete with the virus and reduce its entry into the organism, as has been shown [83] . It should be noted that in Chagas disease with hypercoagulability, with or without associated COVID-19, the incorporation of anticoagulants is important. Considering that heparan sulphate proteoglycans participate in Chagas cardiomyopathy, the initial proposal may favour the use of heparin, heparinoids, or HS mimetics substituted carboxymethyl dextran sulphates or RGTA [84] in treatment. However, there are two important reasons not to use unfractionated heparin (UFH) or heparinoids: the first is the activation of bradykinin receptors through a papain-like enzyme called cruzipain, derived from infective forms of T. Cruzi (Tripomastigotes), this enzyme enhances cell invasion; in addition, heparan sulphate enhances the interaction of molecules of the kinin system, such as high molecular weight kininogen (HK) and cruzipain, which would potentiate cell invasion [85] . Something similar has been reported in COVID-19, a critical imbalance in the renin-angiotensin system (RAS) in combination with decreased ACE expression, increases in ACE2, renin, and angiotensin, which causes the bradykinin cascade to accelerate [86] . The second reason for not using unfractionated heparin or heparinoids is that these molecules would be blocked in all patients with chronic Chagas disease because anti-sulphatide antibodies have been found. These antibodies are inhibited and compete with heparin, dextran sulphate, and chondroitin sulphate [87] . Therefore, it is necessary to consider whether thromboprophylaxis using DOAC is required in patients with Chagas disease and understand the mechanisms of activation and regulation of microthrombosis in COVID-19. More clinical trials are certainly required in these fields. We have reviewed the mechanisms and found some similarities between SARS-CoV-2 and T. cruzi infections. In particular, both clinical entities present microthrombosis and endotheliopathy. Low-molecular weight heparin (LMWH) is commonly used in moderate to severe COVID-19, although some cases do not respond to this, which suggests MBL-MASP-2 pathway activation. On the other hand, in Chagas disease, it is important to carry out further clinical trials and consider thromboprophylaxis using DOAC. Prevalence and risk factors of embolic cerebrovascular events associated with Chagas heart disease Cardiac thrombosis and thromboembolism in chronic Chagas' heart disease Venous thromboembolism in patients with COVID-19: systematic review and meta-analysis Deep vein thrombosis in COVID-19 patients in general wards: prevalence and association with clinical and laboratory variables High prevalence of occult thrombosis in cases of mild/moderate COVID-19 Pulmonary thrombosis in Covid-19: before, during and after hospital admission Unusual arterial thrombotic events in Covid-19 patients COVID-19-associated coagulopathy: an exacerbated immunothrombosis response Altered hypercoagulability factors in patients with chronic chagas disease: potential biomarkers of therapeutic response Host-derived molecules as novel chagas disease biomarkers: hypercoagulability markers in plasma Understanding infection-induced thrombosis: lessons learned from animal models Cunningham AF (2019) Salmonella-induced thrombi in mice develop asynchronously in the spleen and liver and are not effective bacterial traps Thrombocytopenia in critically ill patients due to vascular microthrombotic disease: pathogenesis based on "two activation theory of the endothelium Podoplanin in inflammation and cancer Fucoidan is a novel platelet agonist for the C-type lectin-like receptor CLEC2 and CLEC5A: pathogenic host factors in acute viral infections DAMP and DIC: the role of extracellular DNA and DNA-binding proteins in the pathogenesis of DIC Circulating levels of DNA-histone complex and dsDNA are independent prognostic factors of disseminated intravascular coagulation SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19 SARS-CoV-2 Receptors are Expressed on Human Platelets and the Effect of Aspirin on Clinical Outcomes in COVID-19 Patients Platelets promote thromboinflammation in SARS-CoV-2 pneumonia Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in COVID-19 Mannose-binding lectin is associated with thrombosis and coagulopathy in critically Ill COVID-19 patients Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation Binding capacity of mannose-binding lectin (MBL) is associated with the severity of chronic Chagas cardiomyopathy Deficiency in mannosebinding lectin-associated serine protease-2 does not increase susceptibility to Trypanosoma cruzi infection Genetic Polymorphism at CCL5 Is associated with protection in Chagas' heart disease: antagonistic participation of CCR1 + and CCR5 + cells in chronic chagasic cardiomyopathy Host genetic variants potentially associated with SARS-CoV-2: a multi-population analysis WHO (2020) Chagas disease (also known as American trypanosomiasis) Chagas en la actualidad de Latinoamérica: viejos y nuevos problemas, grandes desafíos Chagas in Latin America today: old and new problems, great challenges A global systematic review of Chagas disease prevalence among migrants Chagas disease Hypercoagulability biomarkers in Trypanosoma cruzi -infected patients 2017) gene expression profiling and functional characterization of macrophages in response to circulatory microparticles produced during Trypanosoma cruzi infection and Chagas disease A preliminary study of platelet hyperactivity in the chronic indeterminate phase of Chagas' disease Mediation of Trypanosoma cruzi invasion by sialic acid on the host cell and trans-sialidase on the trypanosome A neuraminidase from Trypanosoma cruzi removes sialic acid from the surface of mammalian myocardial and endothelial cells Involvement of host cell heparan sulfate proteoglycan in Trypanosoma cruzi amastigote attachment and invasion Trypanosoma cruzi heparin-binding proteins and the nature of the host cell heparan sulfate-binding domain The role of endothelin in the pathogenesis of Chagas' disease Infection-associated vasculopathy in experimental chagas disease pathogenic roles of endothelin and kinin pathways An interactive web-based dashboard to track COVID-19 in real time SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction Megakaryocytes and plateletfibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series Extrapulmonary manifestations of COVID-19 Systematic analysis of ACE2 and TMPRSS2 expression in salivary glands reveals underlying transmission mechanism caused by SARS-CoV-2 Endothelial cell infection and endotheliitis in COVID-19 Circulating endothelial cells in COVID-19 Circulating markers of angiogenesis and endotheliopathy in COVID-19 Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 COVID-19 update: Covid-19-associated coagulopathy Blood coagulation in immunothrombosis-At the frontline of intravascular immunity Platelet gene expression and function in patients with COVID-19 COVID-19 and its implications for thrombosis and anticoagulation 2020) D-Dimer and prothrombin time are the significant indicators of severe COVID-19 and poor prognosis Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Insufficient hyperfibrinolysis in COVID-19: a systematic review of thrombolysis based on meta-analysis and meta-regression. medRxiv Hemostatic changes in patients with COVID-19: a meta-analysis with meta-regressions Hematological findings and complications of COVID-19 Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the Cremona experience Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19 Heparinoid complex-based heparin-binding cytokines and cell delivery carriers Mechanisms of antithrombotic drugs Danaparoid a review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia Sulodexide in venous disease Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans Tissue factor pathway inhibitor release and depletion by sulodexide in humans Interaction of fucoidan with proteases and inhibitors of coagulation and fibrinolysis Heparinoids Danaparoid and Sulodexide as clinically used drugs Heparan sulfate proteoglycans and viral attachment: true receptors or adaptation bias? SARS-CoV-2 evolutionary adaptation toward host entry and recognition of receptor o-acetyl sialylation in virus-host interaction Effective inhibition of SARS-CoV-2 entry by heparin and enoxaparin derivatives Discovering small-molecule therapeutics against SARS-CoV-2 Heparin Inhibits cellular Invasion by SARS-CoV-2: structural dependence of the interaction of the spike s1 receptor-binding domain with heparin Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence Heparan sulfate modulates kinin release by Trypanosoma cruzi through the activity of cruzipain A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm Elevated levels of antibodies against sulphatide are present in all chronic chagasic and dilated cardiomyopathy sera Current epidemiological profile of Chagasic megaesophagus in Central Brazil A 4-year follow-up study of a rural community with endemic Chagas' disease The age pattern of the male-to-female ratio in mortality from COVID-19 mirrors that of cardiovascular disease in the general population Sex and age differences in COVID-19 mortality in Europe Viral load of SARS-CoV-2 across patients and compared to other respiratory viruses Association of Viral Load in SARS-CoV-2 Patients With Age and Gender. Front Med (Lausanne) 8:e608215 Chagas' disease and ageing: the coexistence of other chronic diseases with Chagas' disease in elderly patients Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and metaanalysis of risk factors The Type of Trypanosoma Cruzi Strain (Native or Non-Native) used as substrate for immunoassays influences the ability of screening asymptomatic blood donors Evaluation of asymptomatic patients with chronic Chagas disease through ambulatory electrocardiogram, echocardiogram and B-Type natriuretic peptide analyses A systematic review of asymptomatic infections with COVID-19 Genetic susceptibility to Chagas disease: an overview about the infection and about the association between disease and the immune response genes Human leukocyte antigen susceptibility map for severe acute respiratory syndrome coronavirus 2 Chagas' disease susceptibility/resistance: linkage disequilibrium analysis suggests epistasis between major histocompatibility complex and interleukin-10 L (2016) association of the interleukin-18 receptor 1 and interleukin-18 receptor accessory protein polymorphisms with the risk of esophageal cancer Association of IL18 genetic polymorphisms with Chagas disease in Latin American populations The IL-17A rs2275913 single nucleotide polymorphism is associated with protection to tuberculosis but related to higher disease severity in Argentina Genetic polymorphisms of IL17A associated with Chagas disease: results from a metaanalysis in Latin American populations Genetic polymorphisms of IL17 and chagas disease in the South and Southeast of Brazil New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis Genomewide Association Study of Severe Covid-19 with Respiratory Failure Polymorphisms in genes affecting interferon-γ production and Th1 t cell differentiation are associated with progression to chagas disease cardiomyopathy Role of the IFNG +874T/A polymorphism in Chagas disease in a Colombian population Strong Correlation between the Case Fatality Rate of COVID-19 and the rs6598045 Single Nucleotide Polymorphism (SNP) of the interferon-induced transmembrane protein 3 (IFITM3) gene at the population-level The African-American population with a low allele frequency of SNP rs1990760 (T allele) in IFIH1 predicts less IFN-beta expression and potential vulnerability to COVID-19 infection Sistema ABO e formas anatomoclínicas da doença de Chagas crônica [The ABO system and anatomoclinical forms of chronic Chagas disease ABO, Secretor and Lewis histo-blood group systems influence the digestive form of Chagas disease ABO blood type association with SARS-CoV-2 infection mortality: a single Length and caliber of the rectosigmoid colon among patients with Chagas disease and controls from areas at different altitudes Ethnicity and clinical outcomes in COVID-19: a systematic review and meta-analysis Ethnic disparities in COVID-19 mortality in Mexico: a cross-sectional study based on national data Kininogenase activity by the major cysteinyl proteinase (cruzipain) from Trypanosoma cruzi Interaction of the human contact system with pathogens-an update Inflammatory and prothrombotic activation with conserved endothelial function in patients with chronic, asymptomatic Chagas disease Pretorius E (2020) Erythrocyte, platelet, serum ferritin, and p-selectin pathophysiology implicated in severe hypercoagulation and vascular complications in COVID-19 Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation Biering-Sørensen T (2020) Acute COVID-19 and the incidence of ischemic stroke and acute myocardial infarction Myocardial inflammation and dysfunction in COVID-19-associated myocardial injury Subverting bradykinin-evoked inflammation by co-opting the contact system: lessons from survival strategies of Trypanosoma cruzi C5a and bradykinin receptor cross-talk regulates innate and adaptive immunity in Trypanosoma cruzi infection Inflammation triggered by SARS-CoV-2 and ACE2 augment drives multiple organ failure of severe COVID-19: molecular mechanisms and implications High value of mid-regional proadrenomedullin in COVID-19: a marker of widespread endothelial damage, disease severity, and mortality Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome The authors thank Charlotte Grundy, Maricela Morales Hernández, and Eli Cruz Parada for their technical assistance. We also thank the National Technology of Mexico (TecNM, project 8703.20-P) and the Faculty of Medicine and Surgery, "Benito Juárez" Autonomous University of Oaxaca. The authors have declared no competing interests in this study.